RLX030
-
Novartis provides update on Phase III study of RLX030 serelaxin in patients with acute heart failure
Mar 23, 2017News Hour: Novartis announced results from the global Phase III RELAX-AHF-2 study investigating the efficacy, safety and tolerability of RLX030 (serelaxin) in patients with acute heart failure (AHF). RELAX-AHF-2 did not meet its primary endpoints of reduction...
